Loading...

TOVX THERIVA BIOLOGICS INC US FDA Inspections 8-K Filing

THRV

TVX

THERIVA BIOLOGICS INC

(TOVX)

2025 8-K

Show Summary

Show Summary

Equity Offerings

New Product Launches

Financial Statements

Equity Offerings

Clinical Trials

Clinical Trial Update

Financial Results

FDA Meeting Outcome

Financial Results

Stock Plan Update

Orphan Drug Designation

Clinical Trial Update

Public Offering

Investor Presentations

Funding Announcement

Stock Conversion

Financial Results

FDA Designation and Stock C...

FDA Fast Track Designation ...

Conversion Notice

Financial Results

Amendment to Sales Agreement

Investor Conferences

Financial Results

Clinical Trial Continuation

Regulation FD Disclosure

Clinical Data Presentation

Presentation of Survival Ou...

Annual Meeting Results

Amendments to Bylaws

Earnings Reports

Patient Dosing Initiated in...

Announcement of FDA orphan ...

Earnings Reports

External Links:

On March 31, 2025, Theriva Biologics announced that a review of their VIRAGE Phase 2b clinical trial showed that the treatment VCN-01 was well tolerated with expected side effects, which were less frequent after the second dose.

AI Assistant

THERIVA BIOLOGICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.